Google Fired Workers Protesting Over Cloud Contract Deal With Israel 
Polestar to Launch Polestar 4 Pure EV in South Korea 
Meta AI to Supercharge WhatsApp, Facebook, Instagram via Powerful Integration 
Sony Pictures, Apollo Global Reportedly In Talks to Jointly Bid for Paramount 
Starbucks Revamps Cups to Ease Plastic Waste; New Design to Roll Out in US, Canada 
Huawei Unveils Pura 70 Series to Rival Apple's Dominance in China's Smartphone Arena 
Lotte Wellfood Brings Its Pepero Products to Thailand’s King Power Duty-Free Shop 
Tesla Cybertruck Recall: NHTSA Flags 3,878 Units for Pedal Issue 
LVMH Adds Bernard Aranault’s Sons Frederic and Alexandre Arnault to the Board 
Samsung Implements Emergency 6-Day Work Week to Combat Slowing Growth 
Low pay and few contracts make freelance journalism a bleak prospect in 2024 
Apple Pulls WhatsApp, Threads from China Store; US Moves to Force TikTok Sale 
LG Electronics Eyes $1 Billion Through Bond Deal 
Taeyoung to Sack Executives, Cut Employees' Salaries to Save Company 
Samsung's Exynos 2500 Rumored to Eclipse Snapdragon 8 Gen 4 in Power Efficiency With 3nm SoC 
Adidas Ignites Passion with 2024 Athlete Pack Including 49 Footwear Models 
NEW YORK, Feb. 27, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Innocoll Holdings plc securities (NASDAQ:INNL) from November 3, 2016 through December 29, 2016, both dates inclusive (the “Class Period”) of the important March 27, 2017 lead plaintiff deadline in first-filed class action commenced by the Rosen Law Firm. The lawsuit seeks to recover damages for Innocoll investors under the federal securities laws.
To join the Innocoll class action, go to http://www.rosenlegal.com/cases-1019.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Innocoll’s New Drug Application (“NDA”) submission to the FDA in October 2016 for XARACOLL was incomplete; (2) due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and (3) as a result, Defendants’ statements about Innocoll’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 27, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1019.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
